Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Harnessing Sequence-Specific Long dsRNA to Induce an RNA Interference Response Against Respiratory Viruses in Human Cells

EF 2023-24

Résumé
The proposed research aims to investigate the potential of sequence-specific long double-stranded RNA (dsRNA) molecules to activate an innate immune response via the dsRNA interference (dsRNAi) pathway. dsRNAi is an antiviral innate immune response that utilizes long dsRNA molecules (> 40 bp) to inhibit gene expression. Prophylactic upregulation of the innate immune system through dsRNAi can serve to protect the host against respiratory viral infections, including Respiratory Syncytial Virus (RSV), human coronaviruses (HCoVs), and influenza virus, which are significant global health concerns. These viruses evade long-term vaccine protection and effective antiviral medications. While short interfering RNA (siRNA) has been demonstrated to silence specific viral genes it has a number of shortfalls that are overcome by long, sequence-specific dsRNA. The current project aims to synthesize a single dsRNA molecule containing viral N gene sequences from RSV, HCoV, and influenza. DsRNA’s containing each of these N gene sequences singly are effective at limiting their cognate virus. Human embryonic lung (HEL-299) cells, which are permissive and susceptible to all three chosen virus families, will be used. The study will assess the antiviral protection provided by the sequence-specific dsRNA and compare it to siRNA technology. Its antiviral effects will then be tested in primary bronchial epithelial cells (PBECs) airway cells. While short interfering RNA (siRNA) has shown promise in silencing specific viral genes, the potential multi-family antiviral efficacy of sequence-specific dsRNA is currently unexplored. It is critical to develop antiviral therapeutics that can impact more than one respiratory virus, such as long dsRNA, to improve future patient outcomes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
505953
Name
Cooper Erin S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing Sequence-Specific Long dsRNA to Induce an RNA Interference Response Against Respiratory Viruses in Human Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Long Dsrna; Prophylactic; Respiratory Viruses; Rnai; Viral Reduction
Abstract
The proposed research aims to investigate the potential of sequence-specific long double-stranded RNA (dsRNA) molecules to activate an innate immune response via the dsRNA interference (dsRNAi) pathway. dsRNAi is an antiviral innate immune response that utilizes long dsRNA molecules (> 40 bp) to inhibit gene expression. Prophylactic upregulation of the innate immune system through dsRNAi can serve to protect the host against respiratory viral infections, including Respiratory Syncytial Virus (RSV), human coronaviruses (HCoVs), and influenza virus, which are significant global health concerns. These viruses evade long-term vaccine protection and effective antiviral medications. While short interfering RNA (siRNA) has been demonstrated to silence specific viral genes it has a number of shortfalls that are overcome by long, sequence-specific dsRNA. The current project aims to synthesize a single dsRNA molecule containing viral N gene sequences from RSV, HCoV, and influenza. DsRNA’s containing each of these N gene sequences singly are effective at limiting their cognate virus. Human embryonic lung (HEL-299) cells, which are permissive and susceptible to all three chosen virus families, will be used. The study will assess the antiviral protection provided by the sequence-specific dsRNA and compare it to siRNA technology. Its antiviral effects will then be tested in primary bronchial epithelial cells (PBECs) airway cells. While short interfering RNA (siRNA) has shown promise in silencing specific viral genes, the potential multi-family antiviral efficacy of sequence-specific dsRNA is currently unexplored. It is critical to develop antiviral therapeutics that can impact more than one respiratory virus, such as long dsRNA, to improve future patient outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cooper, Erin S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~